KOWA 303

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).

Biomanufacturing projects stepping out at UW-Madison

Human skin cells (pink) migrating upon a medical device (green) that was manufactured from a parsley leaf. Plant-derived devices are being developed into implants for surgical wound healing with help from the Forward BIO Institute. GIANLUCA …